We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BEZ:LSEBeazley Plc Analysis

Data as of 2026-03-14 - not real-time

£1,288.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Beazley plc is trading at £12.88 (1288 GBp), comfortably above its 20‑day, 50‑day and 200‑day moving averages, indicating a short‑term bullish bias, but the RSI of 77.8 points to an overbought condition and the MACD histogram is negative, signaling bearish momentum. The stock’s PE ratio of 11.9 sits well below the industry average of 16.35, while the dividend yield of 1.94% is supported by a robust cash position of £11.98 bn against modest debt of £0.64 bn, suggesting sustainable payouts. Analyst consensus remains a hold with median price targets around £13.22, yet recent coverage notes a trimmed fair‑value estimate to £12.20 and a split view between earnings strength and underwriting execution risks, adding to near‑term uncertainty.
Over the longer horizon, Beazley’s solid ROE of 19.3%, low beta of 0.23, and stable volume profile underpin a resilient risk profile, while the specialty insurance segments (cyber, MAP, property) offer modest growth opportunities. The combination of strong balance‑sheet metrics, attractive valuation relative to peers, and a sustainable dividend makes the stock a compelling buy for patient investors, despite short‑term technical softness and mixed analyst sentiment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI overbought at 77.8
  • Bearish MACD histogram
  • Mixed analyst targets and recent fair‑value trim

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • PE well below industry average
  • Strong cash generation and low leverage
  • Sustainable dividend yield of 1.94%

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust ROE of 19.3% and solid free cash flow
  • Low beta indicating defensive characteristics
  • Growth potential in specialty lines such as cyber and MAP risks

Key Metrics & Analysis

Financial Health

Revenue Growth1.10%
Profit Margin15.37%
P/E Ratio11.9
ROE19.27%
ROA6.04%
Debt/Equity13.08
P/B Ratio207.9
Op. Cash Flow£1.3B
Free Cash Flow£1.0B
Industry P/E16.4

Technical Analysis

TrendBullish
RSI77.8
Support£1,209.00
Resistance£1,295.00
MA 20£1,258.60
MA 50£1,138.01
MA 200£937.41
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair Value£4,459.15
Target Price£1,318.66
Upside/Downside2.38%
GradeFair
TypeBlend
Dividend Yield1.94%

Risk Assessment

Beta0.23
Volatility23.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.